Biochem Pharmacol
Biochemical Pharmacology
0006-2952
Elsevier Science


1920586
17560554
BCP9420
10.1016/j.bcp.2007.04.024
Article


Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin

Duncan
R.S.

a

McPate
M.J.

a

Ridley
J.M.

a

Gao
Z.

a

James
A.F.

a

Leishman
D.J.

b
c

Leaney
J.L.

b

Witchel
H.J.

harry.witchel@bristol.ac.uk
a
⁎

Hancox
J.C.

jules.hancox@bristol.ac.uk
a
⁎


a
Department of Physiology and Cardiovascular Research Laboratories, School of Medical Sciences, University Walk, Bristol, BS8 1TD, UK

b
Pfizer Global Research & Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK

c
Lilly Research Laboratories, Greenfield Laboratories, PO Box 708, Greenfield IN, 46140, USA

⁎
Corresponding authors
harry.witchel@bristol.ac.uk
jules.hancox@bristol.ac.uk


01
8
2007

74
3
425
437
14
1
2007

27
4
2007


© 2007 Elsevier Inc.
2007
Elsevier Inc.
certain conditions
.


Abstract
I
Kr
I
HERG
I
Kr
I
HERG
50
I
Kr
50
I
HERG
I
HERG
50
I
HERG
 blockade by ∼4.2-fold; the F656A mutant also attenuated doxepin's action at some concentrations. HERG channel blockade is likely to underpin reported cases of QT interval prolongation with doxepin. Notably, this study also establishes doxepin as an effective inhibitor of mutant (N588K) HERG channels responsible for variant 1 of the short QT syndrome.

Keywords
Antidepressant
Arrhythmia
Doxepin
HERG
I
Kr

Long QT syndrome
Potassium channel
QT interval
QT-prolongation
Rapid delayed rectifier
Short QT syndrome
Torsade de pointes




1
Introduction
c
Torsade de Pointes
[1–4]
+
I
Kr
I
Kr
c
[2,4,5]
I
Kr
[6,7]
+
[5,8–10]
c
[11–13]
.
[14]
[15]
[16]
[17]
[14]
[18–20]
c
[19]
[20]
c
[21–23]
I
HERG
I
HERG
 blockade.

2
Methods
2.1
Maintenance of mammalian cell lines stably expressing wild-type and mutant HERG channels
[24]
Fig. 8
+
2.2
[25]
[26]
[27]
[25]
−1
−1
−1
 of hygromycin. The cells were incubated at 37 °C for a minimum of two days prior to any electrophysiological study.

2.2
Experimental solutions
I
HERG
2
2
[28,29]
[8,25]
) and its WT control, the external solution contained 94 mM KCl (the NaCl concentration was correspondingly reduced). Experimental solutions were applied using a home-built, warmed, solution delivery system that exchanged the solution surrounding a cell in <1 s. Doxepin powder (Sequoia Research Products and Sigma-Aldrich) was dissolved in Tyrode's solution to produce initial stock solutions of either 10 or 50 mM, which were serially diluted to produce working solutions ranging from 0.1 μM to 1 mM.
I
HERG
2
[28,29]
. Patch-pipettes were heat-polished to 2.5–4 MΩ. No correction was made for the ‘pipette-to-bath’ liquid junction potential, which was measured to be −3.2 mV.

2.3
Experiments on rabbit isolated ventricular myocytes
I
Kr
Fig. 2
[30,31]
I
Kr
I
HERG
 measurement.

2.4
Electrophysiological recording and analysis
P
 values of less than 0.05 were taken as significant; ns = no statistically significant difference.
The following equations were used for numerical analysis and graphical fits to data:
I
HERG
(1)
Fractional block
=
1
−
I
HERG
–
DOXEPIN



I
HERG
–
CONTROL









I
HERG
I
HERG–DOXEPIN
I
HERG–CONTROL
 represent current amplitudes in the presence and absence of doxepin.
(2)
Fractional block
=
1
1
+
(
I
C
50


/
DOXEPIN
)

h






50
I
HERG
h
 is the Hill coefficient for the fit.
I
HERG
I
HERG
I
V
(3)
I
=
I
max



1
+
exp
V
0.5


−
V
m


k










I
I
HERG
V
m
I
max
I
HERG
V
0.5
I
HERG
k
I
HERG
V
0.5
k
V
0.5
k
Fig. 3
.
I
HERG
(4)
Inactivation parameter
=
1
−
1
1
+
exp
(
V
0.5


−
V
m

)
/
k











V
m
V
0.5
I
HERG
k
 describes the slope factor for the relationship.


3
Results
3.1
I
HERG

I
HERG
Fig. 1
I
HERG
[28,29,32]
I
HERG
I
HERG
I
HERG
I
HERG
Fig. 1
I
HERG
I
HERG
Fig. 1
Fig. 1
I
HERG
50
I
HERG
I
HERG
I
HERG
τ
fast
n
p
τ
slow
p
τ
fast
 was ∼0.6 in both control and doxepin).
I
HERG
[33]
I
HERG
[32,34]
Fig. 2
[32]
Fig. 2
I
HERG
n
I
HERG
Fig. 1
n
p
 > 0.8; unpaired t-test).
I
Kr
[32]
Fig. 2
I
Kr
n
I
Kr
Fig. 2
I
Kr
Fig. 2
(2)
50
I
Kr
I
HERG
.

3.2
I
HERG
 blockade by doxepin
I
HERG
[32]
Fig. 3
Fig. 3
I
HERG
I
HERG
(1)
I
HERG
Fig. 3
Fig. 3
I
HERG
2
V
0.5
k
V
0.5
V
0.5
p
k
k
p
I
HERG
Fig. 3
I
HERG
p
 > 0.2; Anova).
I
HERG
I
HERG
[32,35]
Fig. 3
[35]
Fig. 3
(4)
2
V
0.5
k
I
HERG
I
HERG
p
 > 0.1; obtained from exponential fits to the inactivating phase of the current elicited during the third step of the protocol, following a brief hyperpolarizing step to −80 mV).

3.3
I
HERG
 inhibition by doxepin
I
HERG
HERG
Fig. 4
I
HERG
Fig. 4
I
HERG
Fig. 4
I
HERG
n
I
HERG
K
−1
K
) of 61 ms).
Fig. 4
I
HERG
I
HERG
[29,32]
[29]
I
HERG
[29]
Fig. 5
Fig. 5
Fig. 5
I
HERG
Fig. 5
I
HERG
p
[25,29,36]
.

3.4
I
HERG
 inhibition by doxepin
I
HERG
I
HERG
[26]
[27]
I
HERG
[35,37]
I
HERG
I
HERG
Fig. 1
Fig. 6
Fig. 6
I
HERG
Fig. 6
I
HERG
[26,35,37]
p
p
n
Fig. 6
(2)
I
HERG
50
p
I
HERG
 blockade by doxepin was not highly sensitive to attenuation of HERG channel inactivation.

3.5
I
HERG
 inhibition by doxepin to the S6 mutations Y652A and F656A
[5,9,38]
I
HERG
I
HERG
[29,32,39–41]
Fig. 7
I
HERG
Fig. 7
I
HERG
Fig. 1
Fig. 6
I
HERG
I
HERG
Fig. 7
I
HERG
Fig. 7
I
HERG
Fig. 7
I
HERG
p
I
HERG
Fig. 7
(2)
50
I
HERG
p
50
I
HERG
.
I
HERG
Fig. 8
[25,28,29]
Fig. 1
I
HERG
+
e
I
HERG
Fig. 8
I
HERG
[28]
I
HERG
+
e
2
+
e
Fig. 1
p
Fig. 8
I
HERG
I
HERG
I
HERG
p
I
HERG
I
HERG
p
I
HERG
I
HERG
, though the F656A data did not appear to follow a conventional monotonic concentration dependence.


4
Discussion
[42]
[18–20]
+
I
HERG
[21–23]
I
HERG
 inhibition have been investigated for any member of the TCA family.
4.1
I
HERG
 blockade by doxepin
I
HERG
50
[23]
50
[21]
Xenopus
50
+
e
[22]
I
HERG
50
I
HERG
I
HERG
[22]
[23]
[21–23]
[43]
[44]
I
HERG
I
HERG
I
HERG
I
HERG
I
HERG
Fig. 3
I
HERG
[10,45–48]
.
I
HERG
[23]
[25,49]
[24,49,50]
I
HERG
I
HERG
 inhibition by doxepin in this study is consistent with either a mixed state-dependence of blockade (with components of both closed and open channel blockade) or with the presence of a very rapidly developing component of activation-dependent inhibition immediately on depolarization.
[5,9,38,51]
50
[8]
50
I
HERG
(2)
I
HERG
I
HERG
[25,28]
I
HERG
[43,44]
50
50
[43]
I
HERG
I
HERG
I
HERG
+
e
I
HERG
+
e
+
e
I
HERG
+
e
[28,52]
[53]
[54]
I
HERG
 blockade with brief depolarization and incomplete attenuation of inhibition by the Y652A and F656A mutations, we cannot exclude the possibilities that a proportion of the observed blockade with doxepin involves binding outside of the channel pore, or binding to closed HERG channels.

4.2
I
HERG
 blockade by doxepin
c
[42]
I
HERG
[18–20]
[15]
I
HERG
I
HERG
4.1
Fig. 5
Fig. 2
I
HERG
I
HERG
β
I
Kr
[55]
[51]
I
Kr
[56]
I
HERG
I
Kr
50
I
HERG
I
Kr
[57]
[58]
I
HERG
I
Kr
[59]
I
HERG
I
Kr
I
HERG
I
HERG
I
HERG
 blocking medications.
[27,60]
I
Kr
[27,61]
I
Kr
[62,63]
I
[27,62,63]
I
[63]
I
HERG
I
HERG
 blocking agents in SQT1.



Acknowledgements
RSD was funded by a BBSRC/Pfizer ‘CASE’ studentship. The authors also acknowledge support from the British Heart Foundation (PG/03/121, PG/04/090, PG/06/139) and thank Mrs Lesley Arberry for technical assistance.

References
[1]
Viskin
S.


Long QT syndromes and torsade de pointes
Lancet
1999
354
1625
1633
10560690


[2]
Haverkamp
W.

Breithardt
G.

Camm
A.J.

Janse
M.J.

Rosen
M.R.

Antzelevitch
C.


The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a policy conference of the European Society of Cardiology.
Cardiovasc Res
2000
47
219
233
10947683


[3]
Shah
R.R.


Drugs QT interval prolongation and ICH E14—the need to get it right
Drug Safety
2005
28
115
125
15691222


[4]
Witchel
H.J.

Hancox
J.C.


Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current
Clin Exp Pharmacol Physiol
2000
27
753
766
11022966


[5]
Vandenberg
J.I.

Walker
B.D.

Campbell
T.J.


HERG K+ channels: friend and foe
Trends Pharmacol Sci
2001
22
240
246
11339975


[6]
Sanguinetti
M.C.

Jiang
C.

Curran
M.E.

Keating
M.T.


A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel
Cell
1995
81
299
307
7736582


[7]
Trudeau
M.C.

Warmke
J.W.

Ganetzky
B.

Robertson
G.A.


HERG a human inward rectifier in the voltage-gated potassium channel family
Science
1995
269
92
95
7604285


[8]
Mitcheson
J.S.

Chen
J.

Lin
M.

Culberson
C.

Sanguinetti
M.C.


A structural basis for drug-induced long QT syndrome
Proc Natl Acad Sci USA
2000
97
12329
12333
11005845


[9]
Mitcheson
J.S.

Perry
M.D.


Molecular determinants of high-affinity drug binding to HERG channels
Curr Opin Drug Discov Devel
2003
6
667
674


[10]
Lees-Miller
J.P.

Duan
Y.J.

Teng
G.Q.

Duff
H.J.


Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites
Mol Pharmacol
2000
57
367
374
10648647


[11]
Webster
R.

Leishman
D.

Walker
D.


Towards a drug concentration effect relationship for QT prolongation and torsades de pointes
Curr Opin Drug Discov Devel
2002
5
116
126


[12]
Bridgland-Taylor
M.H.

Hargreaves
A.C.

Easter
A.

Orme
A.

Henthorn
D.C.

Ding
M.


Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks(TM) HT
J Pharmacol Toxicol Meth
2006
54
189
199


[13]
Redfern
W.S.

Carlsson
L.

Davis
A.S.

Lynch
W.G.

MacKenzie
I.

Palethorpe
S.


Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
Cardiovasc Res
2003
58
32
45
12667944


[14]
Pinder
R.M.

Brogden
R.N.

Speight
T.M.

Avery
G.S.

Doxepin Up-To-Date


Review of its pharmacological properties and therapeutic efficacy with particular reference to depression
Drugs
1977
13
161
218
321205


[15]
Dumovic
P.

Burrows
G.D.

Vohra
J.

Davies
B.

Scoggins
B.A.


The effect of tricyclic antidepressant drugs on the heart
Arch Toxicol
1976
35
255
262
989296


[16]
Luchins
D.J.


Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants
Am J Psychiatry
1983
140
1006
1009
6346907


[17]
Roose
S.P.

Dalack
G.W.

Glassman
A.H.

Woodring
S.

Walsh
B.T.

Giardina
E.G.


Is doxepin a safer tricyclic for the heart?
J Clin Psychiatry
1991
52
338
341
1869496


[18]
Baker
B.

Dorian
P.

Sandor
P.

Shapiro
C.

Schell
C.

Mitchell
J.


Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder
J Clin Psychopharmacol
1997
17
15
21
9004052


[19]
Alter
P.

Tontsch
D.

Grimm
W.


Doxepin-induced torsade de pointes tachycardia
Ann Intern Med
2001
135
384
385
11529713


[20]
Rademacher
S.

Dietz
R.

Haverkamp
W.


QT prolongation and syncope with methadone, doxepin, and a beta-blocker
Ann Pharmacother
2005
39
1762
1763
16144878


[21]
Tie
H.

Walker
B.D.

Valenzuela
S.M.

Breit
S.N.

Campbell
T.J.


The heart of psychotropic drug therapy
Lancet
2000
355
1825
11825
10832858


[22]
Jo
S.H.

Youm
J.B.

Lee
C.O.

Earm
Y.E.

Ho
W.K.


Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline
Br J Pharmacol
2000
129
1474
1480
10742304


[23]
Teschemacher
A.G.

Seward
E.P.

Hancox
J.C.

Witchel
H.J.


Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline
Br J Pharmacol
1999
128
479
485
10510461


[24]
Zhou
Z.

Gong
Q.

Ye
B.

Fan
Z.

Makielski
J.C.

Robertson
G.A.


Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature
Biophys J
1998
74
230
241
9449325


[25]
Milnes
J.T.

Crociani
O.

Arcangeli
A.

Hancox
J.C.

Witchel
H.J.


Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652
Br J Pharmacol
2003
139
887
898
12839862


[26]
Zou
A.

Xu
Q.P.

Sanguinetti
M.C.


A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation
J Physiol
1998
509
129
137
9547387


[27]
Brugada
R.

Hong
K.

Dumaine
R.

Cordeiro
J.

Gaita
F.

Borggrefe
M.


Sudden death associated with short-QT syndrome linked to mutations in HERG
Circulation
2004
109
30
35
14676148


[28]
Ridley
J.M.

Milnes
J.T.

Witchel
H.J.

Hancox
J.C.


High affinity HERG K+ channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656
Biochem Biophys Res Commun
2004
325
883
891
15541373


[29]
Duncan
R.S.

Ridley
J.M.

Dempsey
C.E.

Leishman
D.J.

Leaney
J.L.

Hancox
J.C.


Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652
Biochem Biophys Res Commun
2006
341
500
506
16446155


[30]
Hancox
J.C.

Levi
A.J.

Lee
C.O.

Heap
P.


A method for isolating rabbit atrioventricular node myocytes which retain normal morphology and function
Am J Physiol
1993
265
H755
H7666
8368377


[31]
Howarth
F.C.

Levi
A.J.

Hancox
J.C.


Characteristics of the delayed rectifier K current compared in myocytes isolated from the atrioventricular node and ventricle of the rabbit heart
Pflugers Arch
1996
431
713
722
8596721


[32]
Ridley
J.M.

Milnes
J.T.

Hancox
J.C.

Witchel
H.J.

Clemastine


A conventional antihistamine, is a high potency inhibitor of the HERG K+ channel
J Mol Cell Cardiol
2006
40
107
118
16288909


[33]
Kirsch
G.E.

Trepakova
E.S.

Brimecombe
J.C.

Sidach
S.S.

Erickson
H.D.

Kochan
M.C.


Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern
J Pharmacol Toxicol Meth
2004
50
93
101


[34]
Ridley
J.M.

Milnes
J.T.

Zhang
Y.H.

Witchel
H.J.

Hancox
J.C.


Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine
J Physiol
2003
549
667
672
12740430


[35]
McPate
M.J.

Duncan
R.S.

Milnes
J.T.

Witchel
H.J.

Hancox
J.C.


The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: mechanism of gain-in-function determined at 37°C
Biochem Biophys Res Commun
2005
334
441
449
16011830


[36]
Milnes
J.T.

Dempsey
C.E.

Ridley
J.M.

Crociani
O.

Arcangeli
A.

Hancox
J.C.


Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin
FEBS Lett
2003
547
20
26
12860380


[37]
Cordeiro
J.M.

Brugada
R.

Wu
Y.S.

Hong
K.

Dumaine
R.


Modulation of IKr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome
Cardiovasc Res
2005
67
498
509
16039272


[38]
Sanguinetti
M.C.

Mitcheson
J.S.


Predicting drug-HERG channel interactions that cause acquired long QT syndrome
Trends Pharmacol Sci
2005
26
119
124
15749156


[39]
Ridley
J.M.

Dooley
P.C.

Milnes
J.T.

Witchel
H.J.

Hancox
J.C.


Lidoflazine is a high affinity blocker of the HERG K+ channel
J Mol Cell Cardiol
2004
36
701
705
15135665


[40]
Alexandrou
A.J.

Duncan
R.S.

Sullivan
A.

Hancox
J.C.

Leishman
D.J.

Witchel
H.J.


Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin
Br J Pharmacol
2006
147
905
916
16474415


[41]
Ridley
J.M.

Milnes
J.T.

Duncan
R.S.

McPate
M.J.

James
A.F.

Witchel
H.J.


Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656
FEBS Lett
2006
580
1999
2005
16542653


[42]
Reilly
J.G.

Ayis
S.A.

Ferrier
I.N.

Jones
S.J.

Thomas
S.H.L.


QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Lancet
2000
355
1048
1052
10744090


[43]
Kiesecker
C.

Alter
M.

Kathofer
S.

Zitron
E.

Scholz
E.

Thomas
P.D


Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels
Naunyn-Schmiedebergs Arch Pharmacol
2006
373
212
220
16736158


[44]
Ferrer-Villada
T.

Navarro-Polanco
R.A.

Rodriguez-Menchaca
A.A.

Benavides-Haro
D.E.

Sanchez-Chapula
J.A.


Inhibition of cardiac HERG potassium channels by antidepressant maprotiline
Eur J Pharmacol
2006
531
1
8
16423345


[45]
Ficker
E.

Jarolimek
W.

Kiehn
J.

Baumann
A.

Brown
A.M.


Molecular determinants of dofetilide block of HERG K+ channels
Circ Res
1998
82
386
395
9486667


[46]
Herzberg
I.M.

Trudeau
M.C.

Robertson
G.A.


Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels
J Physiol
1998
511
3
14
9679158


[47]
Yang
B.F.

Xu
D.H.

Xu
C.Q.

Li
Z.

Du
Z.M.

Wang
H.Z.


Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels
Acta Pharmacologica Sinica
2004
25
554
560
15132818


[48]
Chen
J.

Seebohm
G.

Sanguinetti
M.C.


Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels
Proc Nat Acad Sci USA
2002
99
12461
12466
12209010


[49]
Witchel
H.J.

Pabbathi
V.K.

Hofmann
G.

Paul
A.A.

Hancox
J.C.


Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents
FEBS Lett
2002
512
59
66
11852052


[50]
Snyders
D.J.

Chaudhary
A.


High affinity open channel block by dofetilide of HERG expressed in a human cell line
Mol Pharmacol
1996
49
949
955
8649354


[51]
Sanguinetti
M.C.

Tristan-Firouzi
M.


HERG potassium channels and cardiac arrhythmia
Nature
2006
440
463
469
16554806


[52]
Wang
S.

Morales
M.J.

Liu
S.

Strauss
H.C.

Rasmusson
R.L.


Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation
FEBS Lett
1997
417
43
47
9395071


[53]
Mitcheson
J.S.

Chen
J.

Sanguinetti
M.C.


Trapping of a Methanesulfonanilide by closure of the HERG potassium channel activation gate
J Gen Physiol
2000
115
229
240
10694252


[54]
Perry
M.

de Groot
M.J.

Helliwell
R.

Leishman
D.

Tristani-Firouzi
M.

Sanguinetti
M.C.


Structural determinants of HERG channel block by clofilium and ibutilide
Mol Pharmacol
2004
66
240
249
15266014


[55]
Abbott
G.W.

Sesti
F.

Splawski
I.

Buck
M.E.

Lehmann
W.H.

Timothy
K.W.


MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Cell
1999
97
175
187
10219239


[56]
Weerapura
M.

Nattel
S.

Chartier
D.

Caballero
R.

Hebert
T.E.


A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current Is MiRP1 the missing link
J Physiol
2002
540
15
27
11927665


[57]
Marshall
J.B.

Forker
A.D.


Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications
Am Heart J
1982
103
401
414
7039280


[58]
Elonen
E.

Linnoila
M.

Lukkari
I.

Mattila
M.J.


Concentration of tricyclic antidepressants in plasma, heart and skeletal muscle after their intravenous infusion to anaesthetized rabbits
Acta Pharmacol Toxicol
1975
37
274
281
(Copenh)


[59]
Leucht
S.

Steimer
W.

Kreuz
S.

Abraham
D.

Orsulak
P.J.

Kissling
W.


Doxepin plasma concentrations: is there really a therapeutic range?
J Clin Psychopharmacol
2001
21
432
439
11476128


[60]
Brugada
R.

Hong
K.

Cordeiro
J.M.

Dumaine
R.


Short QT Syndrome
CMAJ
2005
173
1349
1354
16301704


[61]
Gaita
F.

Giustetto
C.

Bianchi
F.

Schimpf
R.

Haissaguerre
M.

Calo
L.


Short QT syndrome: pharmacological treatment
J Am Coll Cardiol
2004
43
1494
1499
15093889


[62]
Wolpert
C.

Schimpf
R.

Giustetto
C.

Antzelevitch
C.

Cordeiro
J.

Dumaine
R.


Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG
J Cardiovasc Electrophysiol
2005
16
54
58
15673388


[63]
McPate
M.J.

Duncan
R.S.

Witchel
H.J.

Hancox
J.C.


Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome
J Mol Cell Cardiol
2006
41
563
566
16842817




Fig. 1
I
HERG
(2)
50
 value of 6.5 μM (± 1.4 μM) with a Hill coefficient of 1.0 (± 0.2). Each drug concentration was applied to a minimum of five cells.



Fig. 2
I
HERG
I
Kr
I
HERG
I
Kr
I
Kr
(2)
50
 value of 4.4 (± 0.6 μM) with a Hill coefficient of 0.7 (± 0.1). Each drug concentration was applied to a minimum of twelve cells.



Fig. 3
I
HERG
n
I
HERG
I
HERG
2
V
0.5
k
I
HERG
(3)
3
I
HERG
n
I
I
max
(4)
V
0.5
V
0.5
p
k
p
 = 0.59).



Fig. 4
I
HERG
I
HERG
I
HERG
n
K
−1
K
) of 61 ms).



Fig. 5
I
HERG
I
HERG
I
HERG
n
p
 < 0.02).



Fig. 6
I
HERG
I
HERG
I
HERG
Fig. 1
(2)
50
I
HERG
p
p
 < 0.05 between WT and N588K).



Fig. 7
I
HERG
I
HERG
(2)
I
HERG
Fig. 1
n
n
n
n
n
50
I
HERG
I
HERG
p
I
HERG
I
HERG
p
 > 0.05).



Fig. 8
I
HERG
n
p
p
p
 > 0.05).





